Pinned post
My top ten tips for graduating fellows and faculty entering and continuing “early career” as I am transitioning into “mid-career”. A thread:
Andrew J Sauer MD
Verified account This account is verified. Learn more@AndrewJSauer
Cardiologist @MidAmericaHeart, building programs to implement therapies, advance discovery, and foster innovation for patients suffering from heart disease.
2.2K Following 20K Followers 20K Posts
Latest posts 5
Reminder, #AHA26 I’m hosting a reception from 5-8 pm tonight. If you are interested in discussing clinical trials, especially finerenone and heart failure, come by for cocktails and high quality apps on me!
Heading to AHA Scientific Sessions 2026 in Chicago?
I’d love to connect with colleagues interested in what’s next for finerenone in heart failure on Friday evening.
I’m extending an open invitation to investigators, clinicians, and research teams to join us at the University Club of Chicago to learn how the MOONRAKER program is moving forward—and explore opportunities to contribute to this work.
Building on FINEARTS-HF, three complementary phase 3 trials are addressing questions that matter in everyday clinical practice:
• REDEFINE-HF: Evaluating whether finerenone reduces cardiovascular death and first and recurrent HF events in patients hospitalized with acute heart failure and LVEF ≥40%. This will extend the evidence into the vulnerable period surrounding an HF hospitalization.
• CONFIRMATION-HF: Testing an early treatment strategy combining finerenone with an SGLT2 inhibitor across the EF spectrum, assessing whether this approach improves clinical outcomes and patient-reported symptoms compared with usual care following an HF hospitalization.
• FINALITY-HF: Evaluating finerenone in patients with HFrEF who are intolerant of or ineligible for steroidal MRAs, generating evidence on cardiovascular death, HF events, symptoms, and safety in a population with an important unmet treatment need.
Together, these studies will clarify where finerenone fits across HF populations and care settings, including its role in early combination therapy and in patients with limited treatment options.
I’m proud of our Saint Luke's Mid America Heart Institute team’s collaboration with Marc Bonaca, CPC Clinical Research, and investigators worldwide to advance this program.
Whether you’re already involved in MOONRAKER, interested in research collaboration, or simply want to learn more, please join us for an evening of conversation and connection.
📍 University Club of Chicago
76 East Monroe Street, Chicago
Message me for reception details and RSVP. I look forward to seeing you in Chicago!View quoted post on X
Absolutely. True leaders pay the price.
The end of Episode 7, when Jordan said winning has a price and leadership has a price.View quoted post on X
Heading to AHA Scientific Sessions 2026 in Chicago?
I’d love to connect with colleagues interested in what’s next for finerenone in heart failure on Friday evening.
I’m extending an open invitation to investigators, clinicians, and research teams to join us at the University Club of Chicago to learn how the MOONRAKER program is moving forward—and explore opportunities to contribute to this work.
Building on FINEARTS-HF, three complementary phase 3 trials are addressing questions that matter in everyday clinical practice:
• REDEFINE-HF: Evaluating whether finerenone reduces cardiovascular death and first and recurrent HF events in patients hospitalized with acute heart failure and LVEF ≥40%. This will extend the evidence into the vulnerable period surrounding an HF hospitalization.
• CONFIRMATION-HF: Testing an early treatment strategy combining finerenone with an SGLT2 inhibitor across the EF spectrum, assessing whether this approach improves clinical outcomes and patient-reported symptoms compared with usual care following an HF hospitalization.
• FINALITY-HF: Evaluating finerenone in patients with HFrEF who are intolerant of or ineligible for steroidal MRAs, generating evidence on cardiovascular death, HF events, symptoms, and safety in a population with an important unmet treatment need.
Together, these studies will clarify where finerenone fits across HF populations and care settings, including its role in early combination therapy and in patients with limited treatment options.
I’m proud of our Saint Luke's Mid America Heart Institute team’s collaboration with Marc Bonaca, CPC Clinical Research, and investigators worldwide to advance this program.
Whether you’re already involved in MOONRAKER, interested in research collaboration, or simply want to learn more, please join us for an evening of conversation and connection.
📍 University Club of Chicago
76 East Monroe Street, Chicago
Message me for reception details and RSVP. I look forward to seeing you in Chicago!
I’d love to connect with colleagues interested in what’s next for finerenone in heart failure on Friday evening.
I’m extending an open invitation to investigators, clinicians, and research teams to join us at the University Club of Chicago to learn how the MOONRAKER program is moving forward—and explore opportunities to contribute to this work.
Building on FINEARTS-HF, three complementary phase 3 trials are addressing questions that matter in everyday clinical practice:
• REDEFINE-HF: Evaluating whether finerenone reduces cardiovascular death and first and recurrent HF events in patients hospitalized with acute heart failure and LVEF ≥40%. This will extend the evidence into the vulnerable period surrounding an HF hospitalization.
• CONFIRMATION-HF: Testing an early treatment strategy combining finerenone with an SGLT2 inhibitor across the EF spectrum, assessing whether this approach improves clinical outcomes and patient-reported symptoms compared with usual care following an HF hospitalization.
• FINALITY-HF: Evaluating finerenone in patients with HFrEF who are intolerant of or ineligible for steroidal MRAs, generating evidence on cardiovascular death, HF events, symptoms, and safety in a population with an important unmet treatment need.
Together, these studies will clarify where finerenone fits across HF populations and care settings, including its role in early combination therapy and in patients with limited treatment options.
I’m proud of our Saint Luke's Mid America Heart Institute team’s collaboration with Marc Bonaca, CPC Clinical Research, and investigators worldwide to advance this program.
Whether you’re already involved in MOONRAKER, interested in research collaboration, or simply want to learn more, please join us for an evening of conversation and connection.
📍 University Club of Chicago
76 East Monroe Street, Chicago
Message me for reception details and RSVP. I look forward to seeing you in Chicago!
